



Xinmai Yang,1 Erich W. Stein,1 S. Ashkenazi2 and Lihong V. Wang1,∗
Nanoparticles have been designed and applied as contrast enhancers in various
optical imaging techniques, such as optical coherence tomography, fluorescence
imaging, and optical reflectance microscopy. As an emerging hybrid imaging
modality, photoacoustic imaging (PAI) has also benefited from the application
of these nanoparticle-based contrast agents. We review this rapidly growing
field and describe the applications of nanoparticles in PAI. Particular focus is
given to nanoparticles whose absorption mechanism is based on surface plasmon
resonance, including gold nanoshells, nanorods, and nanocages. Dye-embedded
nanoparticles are also reviewed. Specifically, the design and application of each
nanoparticle-based contrast agent in relation to the field of PAI are detailed.  2009
John Wiley & Sons, Inc. WIREs Nanomed Nanobiotechnol 2009 1 360–368
Photoacoustic imaging (PAI), also called optoa-coustic or thermoacoustic imaging, has emerged
as a promising non-invasive imaging modality1–6 that
combines the spectral selectivity of molecular exci-
tation by laser light with the high resolution of
ultrasound imaging. Currently, two PAI techniques
are actively studied: photoacoustic tomography (PAT)
and photoacoustic microscopy (PAM).6–8 Typically,
PAT utilizes either an ultrasound detector array or
single scanned detector (to mimic an array) and an
inverse algorithm to reconstruct cross-sectional or
three-dimensional images of biological tissue. In con-
trast to PAT, PAM typically uses a raster-scanned
focused ultrasonic detector coupled with confocal
optical illumination and requires no reconstruction
algorithm. Additionally, the optical-ultrasonic confo-
cal configuration improves the signal-to-noise ratio.
PAI takes advantage of the high optical con-
trast of biological tissue. Because of the high optical
absorption of hemoglobin over a broad optical spec-
trum, PAI has been proven to be a powerful tool for
imaging blood vessels. PAI has also been used to track
the uptake, delivery, and excretion of optical tracers
in vivo.9–11. Thus, PAI is suitable for monitoring both
endogenous and exogenous optical contrast agents
such as hemoglobin and organic dyes, respectively.12
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Advances in nanotechnology have produced signif-
icant contributions by means of nanoparticle-based
contrast agents, which vary in diameter from 1 nm
to several hundred nanometers.13,14 Furthermore, the
surface characteristics of these nanoparticles can be
engineered to enhance biocompatibility.
Nanoparticles designed for high photoacoustic
contrast can be classified into two major types based
on the physical mechanism of light absorption: par-
ticles based on surface plasmon resonance (SPR) and
dye-containing nanoparticles. For SPR applications,
nanoscale metallic films, most commonly gold, are
deposited onto the nanoparticle surface. Peak absorp-
tion can be tuned throughout the visible and near
infrared (NIR) regions by simply controlling the physi-
cal dimensions of the metallic layer.15,16 Furthermore,
gold surfaces exhibit excellent biocompatibility and
are a simple means to add additional surface function-
alities. Dye-containing nanoparticles, however, utilize
a high payload of NIR organic dyes to enhance optical
absorption. For example, indocyanine green (ICG), an
Food and Drug Administration (FDA)-approved dye,
has been encapsulated within nanoparticles and used
as a contrast enhancer for PAI.17
The use of nanoparticle-based contrast agents
greatly extends PAI applications. (1) It allows PAI to
image deeper within tissue with enhanced contrast.
Nanoparticles are usually designed with peak absorp-
tion in the NIR region, where optical attenuation
of tissue is relatively low, affording deep light pene-
tration. (2) Targeting peptides and antibodies can be
conjugated to the nanoparticle surface for cell specific
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FIGURE 1 | SEM image of ICG PEBBLE (a) and optical absorption of
ICG PEBBLEs and ICG free dye at different concentrations (b).
Comparison yields a mean loading of 23000 ICG molecules per
nanoparticles (Reproduced with permission from Ref 42. Copyright
2007 SPIE).
contrast and molecular imaging. (3) Potentially, PAI
can be easily combined with photothermal therapy,
because both techniques share similar mechanisms.
In the following, we will review the design, syn-
thesis, characterizations, and application of different
types of nanoparticle-based PAI contrast agents. The
focus will be on gold nanoshells, gold nanorods, gold
nanocages, and ICG-doped nanoparticles, which are
contrast agents studied in PAI.
CHARACTERIZATION OF
NANOPARTICLES IN PAI
Of the four kinds of nanoparticles used in PAI,
nanoshells were the first to be adopted. Nanoshells
usually consist of a dielectric core coated by a conduc-
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FIGURE 2 | (Comparison of the optical spectra calculated using DDA
for gold nanorods, nanoshells, and nanocages. For all the structures, the
SPR peak was tuned to exactly 800 nm. (a) The gold nanorod has a
width of w = 20 nm and length L = 66 nm. (b) The nanoshell has a
silica core of 50 nm in diameter and shell thickness of 3.2 nm. (c) The
nanocage has a water core with an inner edge length of 50 nm and wall
thickness of 6 nm. (Reproduced with permission from Ref 33. Copyright
2006 The Royal Society of Chemistry).
Consequently, alterations in core size and/or shell
thickness shift the SPR, allowing nanoparticle opti-
cal properties (absorption and scattering) to be tuned
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over the visible and NIR spectral regions.19,20 This
level of tunability is a highly attractive property,
affording biomedical applications from sensing to
imaging.14,21 Particularly, nanoshells have been engi-
neered with absorption peaks ranging from 600 to
900 nm, a spectral region lying within the tissue ‘opti-
cal window’ where absorption is minimal and optical
penetration is maximal.22 In additional to favor-
able spectral characteristics, nanoshells have been
proven to be optically robust, exhibiting resistance to
chemical/thermal denaturation and photobleaching,
commonplace effects that compromise the longevity
of NIR dyes.23,24 Furthermore, nanoshells comprising
gold offer a straightforward means to chemically mod-
ify surface characteristics (and modulate host response
when used in vivo) by grafting on functional groups
ranging from polyethylene glycols to integrins.25
Gold nanorods represent another kind of
nanoparticles whose absorption mechanism is based
on SPR. Unlike nanoshells, nanorods exhibit cylin-
drical symmetry, and simple changes in particle sym-
metry can significantly alter SPR characteristics. Like
nanoshells, nanorods have strong resonance optical
absorption, a property attributed to their shape.26,27
In contrast, nanorods can be made smaller (tens of
nanometers) than nanoshells, increasing their effi-
ciency in targeting specific cellular receptors.
With a more complicated shape, gold nanocages
represent a novel class of optically tunable nanoparti-
cles with cuboidal symmetry.28–30 It has been demon-
strated that nanocages can be melted by a camera flash
discharge because of their high optical absorption.31
They are prepared by a simple galvanic replacement
reaction between Ag nanocubes and HAuCl4. By
adjusting the amount of HAuCl4 added, the SPR
peaks of the resultant Au nanocages can be precisely
tuned throughout the visible and NIR regions. For in
vivo use, gold nanoparticles are typically PEGylated
prior to introduction into the host.
In addition to regular geometries such as shells
and rods, other SPR nanoparticles with even more
complex shapes have been designed, such as multi-
pods, star shapes, lumps, etc.32 These nanoparticles
can display well-defined peaks in the ensemble spectra,
which are determined by their shapes. However, to
date, there is no published work on the application of
these nanoparticles in PAI.
Various methods have been demonstrated for
preparing gold nanoparticles and have been docu-
mented else where, and interested readers are referred
to Refs 31,33–37 for details.
Nanoparticles that do not rely on SPR absorp-
tion have also been proposed for PAI. Nanoparticles
(100 nm in diameter) containing ICG have been
developed as a contrast agent for PAI based on
photonic explorers for biomedical use by biologically
localized embedding (PEBBLE) technology,38–40 using
organically modified silicate (ormosil) as a matrix (see
Figure 1(a)).41–43 This technology, originally devel-
oped for sensing and therapeutic applications, allows
the incorporation of sensor dyes, imaging contrast
agents, drugs, photosensitizers for photodynamic
therapy (PDT), and cell-targeting ligands in a nano-
size biocompatible particle. ICG has strong optical
absorption in the NIR region, and contrast enhance-
ment in PAI by ICG in its free dye form has been
demonstrated.10 However, free dye ICG has a half-life
of only several minutes inside the blood stream.
Dye encapsulation in nanoparticles significantly
increases the circulation time in blood,42 allowing
for an extended imaging period. Dye encapsulation
has several other advantages. First, the nanoparticle
surface can be engineered for specific purposes,
for example, incorporating a targeting moiety for
selective contrast enhancement. Second, superior
contrast is achieved because of the high dye concen-
tration in the nanoparticle. Finally, encapsulation in a
nanoparticle stabilizes ICG dye molecules against the
effects of an aqueous medium and other destabilizing
effects from the biological environment. More details
about the preparation can be found in Ref.42.
Optical absorption spectra of ICG-ormosil
PEBBLEs (Figure 1(b)) indicate efficient entrapping
of ICG dye in the nanoparticle matrix (23,000 dye
molecules per single nanoparticle). The matrix’s high
affinity for ICG acts to stabilize the dye against
aggregation and to retain its high optical absorption
even at extremely high dye concentrations. The
ormosil encapsulation is also efficient in protecting
the dye from the environment. ICG-ormosil PEBBLEs
showed improved stability in aqueous solution
compared with free ICG dye.
THEORETICAL COMPARISONS OF
OPTICAL ABSORPTION
Unlike most traditional optical imaging techniques,
in PAI, the signal from photoacoustic effect is pro-
portional to optical absorption. Naturally, the most
critical requirement for PAI contrast agents is high
optical absorption. A study by Hu et al.33 compared
the different nanostructures in the context of biomed-
ical applications, where the exact magnitudes of both
scattering and absorption are important. Figure 2
compares the absorption, scattering, and extinction
spectra calculated for gold nanorods, nanoshells, and
nanocages using the discrete dipole approximation
(DDA) method. In these results, the dimensions of the
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structures were adjusted to tune their SPR peaks to
800 nm, which is the typical wavelength chosen in
the NIR range in biomedical applications. This wave-
length requires gold nanorods with an aspect ratio of
3.3 and a fixed width of 20 nm, gold nanoshells on
silica cores with a core diameter of 50 nm and shell
thickness of 3.2 nm, and gold nanocages with an inner
edge length of 50 nm and wall thickness of 6 nm. The
comparisons are based on cross-sections. It is worth
noting that gold nanocages and nanorods have much
larger absorption and scattering cross-sections than
gold nanoshells: i.e., Ccage ≈ Crod > t Cshell.
A side by side comparison between ICG-ormosil
PEBBLEs and SPR nanoparticles is not available in the
literature. However, because ICG-ormosil PEBBLEs
encapsulate ∼ 23,000 dye molecules per single
nanoparticle, the absorption of these nanoparticles
may be at the same order of magnitude as SPR
particles. (The absorption of gold nanoparticles is
about four to five orders of magnitude stronger
comparing free ICG).
ON-GOING WORK
The initial application of nanoshells as a photoacous-
tic contrast agent was to increase the NIR contrast
of cortical blood vessels in the in vivo rat brain.9
Nanoshells comprising PEGylated surfaces (half-life of
∼ 3.7 h in blood) with a mean diameter of ∼ 135 nm
and peak absorption of 800 nm were injected into the
tail vein of Sprague–Dawley rats. Cortical vascula-
ture was non-invasively imaged using PAT following
nanoshell injections (three in total). Successive image
acquisition was used to quantify circulation dynamics,
including clearance, in the cortical blood stream (Fig-
ure 3). Comparison of the image acquired using only
endogenous contrast (Figure 3(a)) to that acquired
after the third administration of nanoshells (Fig-
ure 3(b)) demonstrated a substantial increase in vas-
cular contrast because of the presence of nanoshells in
the blood stream. The difference in the post- and pre-
injection images (Figure 3(c)) depicted the nanoshell
distribution within the cortical vasculature. Further-
more, the mean photoacoustic amplitude, which is
proportional to volume-specific optical absorption, of
the cortical vasculature for each successive image was
calculated and plotted versus time (Figure 3(d)). Fol-
lowing three sequential nanoshell doses, these data
depicted a 63% increase in blood vessel absorption.
This work illustrated the feasibility of using nanoshells
in vivo as an NIR contrast agent in PAI, with par-
ticular implications in enhancing the sensitivity of
cortical blood volume measurements in non-invasive
studies of small animal brain function.5 While this
FIGURE 3 | (a) Noninvasive in vivo photoacoustic
image of rat cortical vasculature acquired using 800 nm
irradiation before administration of nanoshells as a NIR
contrast agent. MF: median fissure. (b) Photoacoustic
image acquired ∼20 min post-injection of the third dose of
nanoshells. (c) Difference image obtained by subtracting
pre- and post-injection images (i.e. Image C = Image
B—Image A). (d) Mean optical absorption of cortical
vasculature normalized to the mean optical absorption
prior to nanoshells administration. (Reproduced with
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λ = 532 nm λ = 680 nm
FIGURE 4 | Darkfield,
ultrasound and optoacoustic
images (λ = 532 nm and
680 nm) of control, targeted and
non-targeted tissue phantoms.
The darkfield images measure
440 µm by 340 µm field of
view. The ultrasound and
optoacoustic images measure
2 mm by 1.67 mm. (Courtesy of
Dr. Emelianov) (Reproduced
with permission from Ref 47.
Copyright 2007 Optical Society
of America).
report showed the feasibility of nanoshells as NIR
contrast agents, nanoshells were initially designed for
applications in photodynamic therapies.14,23,44
Others have shown that nanoshells or other
nanoscale particles tend to passively accumulate in
tumor regions via the enhanced permeability and
retention effect, a mechanism attributed to an increase
in vascular porosity.45 Indeed, extravasation from
healthy vasculature is virtually non-existent, resulting
in increased NIR contract in the peripheral tumor
vasculature. Reflection-mode PAI7 was used to image
nanoshell extravasation from the surrounding vas-
culature of a subcutaneous murine tumor.46 These
results showed nanoshell accumulation within the
tumor periphery, with minimal accumulation in the
tumor core, results which were histologically verified.
Furthermore, dynamic studies of nanoshell accumula-
tion in subcutaneous tumors showed eventual clearing
from the vasculature, with progressive uptake in
the tumor periphery. The contrast ratio between the
tumor cortex and the surrounding vasculature was 2
to 1, indicating that PAI with nanoshell contrast could
aid in the detection of cancers. The future direction of
this work is focused on integrating PAI and PDT to
provide seamless detection and treatment of cancers.
In a study conducted at UT Austin,47 PAI
was performed at 532 and 680 nm on three tissue
phantoms prepared using A431 skin cancer cells
targeted with anti-epidermal growth factor receptor
gold bioconjugates (Figure 4). The results of this
study demonstrated that using molecular-targeted
gold nanoparticles and PAI allowed specific molecular
differentiation and highly sensitive and selective
detection of skin cancers.
The in vivo detection of gold nanorods (Fig-
ure 5) by a PAT system has been recently performed
and showed promising results.48 The in vivo tar-
geting property of nanorods was also demonstrated
for human prostate cancer.49 This study described
cancer cell targeting by gold nanorods conjugated
with an antibody and demonstrated PAI of a sin-
gle layer of cells. The specific nanoparticle complex
was designed for peak absorption in the range of
700–840 nm, optimal for in vivo applications. In a
more recent study, gold nanorods were also shown
to be capable of targeting multiple molecules.50 In
this study, two corresponding monoclonal antibodies
were conjugated to nanorods with different aspect
ratios to target HER2 and CXCR4 molecules. The
approach may allow the expression levels of dif-
ferent oncogenes within cancer cells to be revealed
simultaneously. Another study used antibody conju-
gated gold nanorods as a molecular-specific contrast
agent to improve the sensitivity of PAI for imaging
20 mm
(a) (b)
FIGURE 5 | A typical optoacoustic image of a nude mouse before (a)
and after (b) subcutaneous injection of 100 µL of Au-NRs at a
concentration of 7.5 × 1010 NRs per mL in the abdominal area. Injected
nanoparticles were brightly visible in the optoacoustic image
(b).Drawing in (a) depicts the approximate position of the nude mouse
during experiment. (Reprinted with permission from Ref 48. Copyright
2007 American Chemical Society).
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FIGURE 6 | Targeted gold nanoparticles binding to cell membrane.
Scale bar: 200 nm (Courtesy of Dr. Li), (Reproduced with permission
from Ref 52. Copyright 2006 SPIE).
of breast tumors.51 Cancer cells exhibited enhanced
contrast in PAI images because of the presence of
nanorods on their surface, whereas the negative con-
trol (no nanorods) and cells exposed to nanorods alone
(nanorods not conjugated to Herceptin) exhibited no
substantial contrast enhancement. Transmission elec-
tron microscopy imaging of targeted cells showed
effective binding of nanorods to cell membranes (Fig-
ure 6)52 and internalization by endocytosis of gold
nanospheres (Figure 7).27 Antibody conjugated gold
nanorods targeted to tumor cells improved the sensi-
tivity of PAI for early detection of deep tumors.
The feasibility of PAI of inflammatory responses
using bioconjugated gold nanorods was demonstrated
ex vivo.53 Gold nanorods were conjugated to anti-
intercellular adhesion molecule-1, and stimulated
endothelial cells labeled with bioconjugated gold
nanorods were scanned using a high frequency
transducer. The results demonstrated that PAI could
differentiate between inflamed cells, which were
targeted with PA contrast agents, and control cells.
Owing to the biocompatibility and well-
established surface chemistry of Au, the optical prop-
erties of Au nanocages have also been explored for a
number of biomedical applications.33,54 For example,
it has recently been demonstrated that Au nanocages
provide enhanced image contrast when integrated
with optical coherence tomography (OCT), an imag-
ing modality capable of resolving tissue microanatomy
in vivo using predominantly scattering contrast.55,56
Additionally, Au nanocages functionalized with tar-
geting moieties have been shown to preferentially
accumulate on the surface of cancer cells. The subse-





FIGURE 7 | Electron microphotographs of SK-BR-3 cells incubated
with Mab/NP. (a) SEM showing two NP (arrowheads) directly on the cell
surface. mv - microvilli. (b) TEM of an ultrathin section. NP adherent to
the cell surface (arrowhead) and to the surface of microvilli (thin
arrows) or in the process of internalization (thick arrows) into vesicles;
(c) TEM of an ultrathin section. NP internalized in a cytoplasmic vesicle
(open arrow). Scale bars 0.5 micrometers. (Courtesy of Dr. Oraevsky)
(Reprinted with permission from Ref 27. Copyright 2004 Elsevier
Limited).
Au nanocages resulted in the selective photothermal
destruction of cancer cells in vitro.57. A recent in
vivo study showed that Au nanocages can effectively
enhance PAI when injected into the blood stream
during the imaging of a rat cerebral cortex.11
ICG-embedded nanoparticles have been conju-
gated with HER2 antibody for breast cancer and
prostate cancer cell targeting.42. Initial in vitro char-
acterization shows high contrast and high efficiency
for binding to prostate cancer cells. ICG is also a
photosensitizer, able to produce highly reactive sin-
glet oxygen by energy transfer from photoexcited dye
molecules to oxygen molecules. Photosensitizers were
used in PDT as a light-activated cancer therapy. Pho-
tosensitization of ICG-ormosil PEBBLEs was found to
be suitable for clinical PDT applications.
DISCUSSIONS AND CONCLUSION
Among the four kinds of nanoparticles employed in
PAI so far, nanorods seem to have advantages as
optical absorbers. Au nanocages have similar optical
absorption to Au nanorods. Additionally, nanocages
are capable of encapsulating drugs. The advantages of
ICG-based nanoparticles largely rely on the fact that
ICG is the FDA-approved dye for routine clinical use.
All the nanoparticles used are very stable, i.e.,
non-bleaching, and can last several hours inside the
body. There is still a rich array of contrast agents
for PAI under testing, such as Au nano colloids,
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carbon nanotubes, etc. All of these contrast agents are
non-photobleaching and long-circulating nanoparti-
cles with good optical absorption. Other nanoparticles
with strong optical absorption have the potential to
become the contrast agents for PAI. However, to date,
none of the tested nanoparticles can enhance opti-
cal contrast by a factor of two in vivo in the blood
stream. A remaining question is whether nanoparticles
are safe to use in human beings, although there are
no obvious adverse effects reported in small animal
experiments. This question will need further study
before FDA approval is sought.
As an example of future applications, SPR
nanoparticles have started to see use in photothermal
therapy.44,58 Because SPR nanoparticles are good can-
didates for PAI, future study in combining PAI and
photothermal therapy with the aid of SPR nanoparti-
cles will be very attractive.
The optimal shape of SPR nanoparticles will
also need to be studied further. Currently, because of
the limited work in PAI, it is impossible to conclude
which kind of nanoparticles is best. The chances are
that there is probably no ‘best’; instead, every kind
of nanoparticles may be best suitable for a certain
application. In addition, because shape, size, materi-
als, and mechanisms of different nanoparticles vary,
proper comparisons between nanoparticles need to be
justified.
For future applications, PEBBLEs represent a
versatile platform for PAI. Besides enhancing contrast
and cell targeting, PEBBLEs can carry sensor dyes and
PDT agents. Sensor dyes incorporated in PEBBLEs
would allow functional PAI of tissue parameters, such
as pH, glucose, dissolved oxygen level, calcium con-
centration, and cell membrane potential. This would
provide clinical in vivo imaging of tissue metabolism
and functionality, so far available only for in vitro
cellular analysis. PDT dye-embedded PEBBLEs have
already been studied for brain tumor targeting and
treatment.59 Combined with photoacoustic contrast
agents, PEBBLEs could provide diagnosis and therapy
in a single agent.
In conclusion, advances in nanotechnology have
yielded applications in PAI technique. Particularly,
the development of nanoscale contrast agents for PAI
has allowed researchers to obtain enhanced contrast
in the NIR region, where tissue optical absorption is
minimized. This capability has afforded applications
in deep-tissue imaging. Furthermore, the develop-
ment of ligand-targeting contrast agents has resulted
in the ability to image molecular distributions in
vivo with enhanced contrast, potentially improving
the ability of early disease detection. Current work
in nanoscale contrast agents for PAI is focused on
optimizing absorption properties, as well as adding
additional functionalities and ‘smart’ features. This
next generation of contrast agents is expected to yield
developments in the combination of seamless detec-
tion and treatment of diseases.
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